Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651584 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
A Phase 3 study, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 428
- Enrollment target
NCT02651584 is a Phase 3 study that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 428 participants.
The verdict
NCT02651584, a Phase 3 study, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 428 participants
- Enrollment target
Study Summary
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and maintenance treatment with BPN.
Interventions
- DRUG CAM2038 SC injection
- DRUG SL BPN/NX tabs
- DRUG placebo SC injections
- DRUG SL placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02651584
The ClinicalTrials.gov registry entry for NCT02651584 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 428 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braeburn Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CAM2038 SC injection is the first listed.
NCT02651584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02651584 about?
NCT02651584 is a clinical study titled "Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence". Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and maintenance treatment with BPN.
What is the current status of trial NCT02651584?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 2015-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02651584?
The interventions under investigation include: CAM2038 SC injection (DRUG), SL BPN/NX tabs (DRUG), placebo SC injections (DRUG), SL placebo tablets (DRUG).
Who is sponsoring clinical trial NCT02651584?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.